Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 8,294 $ 16,522
Note receivable - LINICO 450 600
Accounts receivable 0 67
Inventory 1,040 929
Prepaid expenses and other current assets 296 181
Total current assets 10,080 18,299
Non-current assets    
Property, plant and equipment, net 14,453 10,347
Intellectual property, net 236 281
Other assets 6,677 4,673
Total non-current assets 21,366 15,301
Total assets 31,446 33,600
Current liabilities    
Accounts payable 1,997 1,836
Accrued Expenses 3,231 2,467
Lease liability, current portion 253 275
Note payable, current portion 2,970 35
Total current liabilities 8,451 4,613
Lease liability, non-current portion 143 0
Note payable, non-current portion 0 2,923
Total liabilities 8,594 7,536
Commitments and contingencies (see Note 12)
Stockholders’ equity    
Common stock; $0.001 par value; 200,000,000 shares authorized; 113,131,561 and 112,674,915, shares issued and outstanding as of March 31, 2024, respectively and 108,308,661 and 107,880,095, shares issued and outstanding as of December 31, 2023, respectively 113 108
Additional paid-in capital 252,066 249,687
Accumulated deficit (228,967) (223,215)
Treasury stock, at cost; common shares: 456,646 and 428,566 as of March 31, 2024 and December 31, 2023, respectively (360) (516)
Total stockholders’ equity 22,852 26,064
Total liabilities and stockholders’ equity $ 31,446 $ 33,600